Literature DB >> 10070859

Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma.

H E Feilotter1, V Coulon, J L McVeigh, A H Boag, F Dorion-Bonnet, B Duboué, W C Latham, C Eng, L M Mulligan, M Longy.   

Abstract

We examined a panel of sporadic breast carcinomas for loss of heterozygosity (LOH) in a 10-cM interval on chromosome 10 known to encompass the PTEN gene. We detected allele loss in 27 of 70 breast tumour DNAs. Fifteen of these showed loss limited to a subregion of the area studied. The most commonly deleted region was flanked by D10S215 and D10S541 and encompasses the PTEN locus. We used a combination of denaturing gradient gel electrophoresis and single-strand conformation polymorphism analyses to investigate the presence of PTEN mutations in tumours with LOH in this region. We did not detect mutations of PTEN in any of these tumours. Our data show that, in sporadic breast carcinoma, loss of heterozygosity of the PTEN locus is frequent, but mutation of PTEN is not. These results are consistent with loss of another unidentified tumour suppressor in this region in sporadic breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070859      PMCID: PMC2362663          DOI: 10.1038/sj.bjc.6690115

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  57 in total

1.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases.

Authors:  H C Tsou; D H Teng; X L Ping; V Brancolini; T Davis; R Hu; X X Xie; A C Gruener; C A Schrager; A M Christiano; C Eng; P Steck; J Ott; S V Tavtigian; M Peacocke
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

3.  PTEN1 is frequently mutated in primary endometrial carcinomas.

Authors:  D Kong; A Suzuki; T T Zou; A Sakurada; L W Kemp; S Wakatsuki; T Yokoyama; H Yamakawa; T Furukawa; M Sato; N Ohuchi; S Sato; J Yin; S Wang; J M Abraham; R F Souza; K N Smolinski; S J Meltzer; A Horii
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

4.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

5.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

Authors:  P Cairns; K Okami; S Halachmi; N Halachmi; M Esteller; J G Herman; J Jen; W B Isaacs; G S Bova; D Sidransky
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

6.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

Authors:  E Rhei; L Kang; F Bogomolniy; M G Federici; P I Borgen; J Boyd
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

7.  PTEN/MMAC1 mutations in endometrial cancers.

Authors:  J I Risinger; A K Hayes; A Berchuck; J C Barrett
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

8.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

9.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Authors:  B K Rasheed; T T Stenzel; R E McLendon; R Parsons; A H Friedman; H S Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

10.  Cowden's disease: a cutaneous marker of breast cancer.

Authors:  M H Brownstein; M Wolf; J B Bikowski
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

View more
  36 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

4.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

5.  The gene for human TATA-binding-protein-associated factor (TAFII) 170: structure, promoter and chromosomal localization.

Authors:  J A Van Der Knaap; V Van Den Boom; J Kuipers; M J Van Eijk; P C Van Der Vliet; H T Timmers
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

6.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody.

Authors:  Nicolas Chapuis; Jérôme Tamburini; Pascale Cornillet-Lefebvre; Lucile Gillot; Valérie Bardet; Lise Willems; Sophie Park; Alexa S Green; Norbert Ifrah; François Dreyfus; Patrick Mayeux; Catherine Lacombe; Didier Bouscary
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

7.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Authors:  Nathalie Dourdin; Babette Schade; Robert Lesurf; Michael Hallett; Robert J Munn; Robert D Cardiff; William J Muller
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis.

Authors:  Lin Yuan; Yanrong Lv; Hongchang Li; Haidong Gao; Shanshan Song; Yuan Zhang; Guichun Xing; Xiangzhen Kong; Lijing Wang; Yang Li; Tao Zhou; Daming Gao; Zhi-Xiong Xiao; Yuxin Yin; Wenyi Wei; Fuchu He; Lingqiang Zhang
Journal:  Nat Cell Biol       Date:  2015-08-17       Impact factor: 28.824

9.  Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing Field.

Authors:  Fernanda Ledda; Gustavo Paratcha
Journal:  Biomark Insights       Date:  2007-02-14

10.  Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.

Authors:  Emily A Nizialek; Charissa Peterson; Jessica L Mester; Erinn Downes-Kelly; Charis Eng
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.